Skip to main content
CAMBRIDGE COGNITION HOLDINGS PLC logo

CAMBRIDGE COGNITION HOLDINGS PLC — Investor Relations & Filings

Ticker · COG ISIN · GB00B8DV9647 LEI · 213800SZKDIN122EPA96 IL Professional, scientific and technical activities
Open in API
Filings indexed 351 across all filing types
Latest filing 2026-04-24 Report Publication Anno…
Country GB United Kingdom
Listing IL COG

About CAMBRIDGE COGNITION HOLDINGS PLC

https://www.cambridgecognition.com/

Cambridge Cognition Holdings PLC is a neuroscience technology company that develops and markets digital solutions to assess brain health. The company provides an end-to-end platform for Central Nervous System (CNS) clinical trials, featuring a suite of scientifically validated digital cognitive assessments. Its technologies include touchscreen tests, voice analysis, electronic questionnaires, and high-frequency testing, which can be deployed both in-clinic and remotely for decentralized trials. These tools are utilized by pharmaceutical companies, academic research institutions, and healthcare professionals to accelerate drug development and enhance the understanding and treatment of conditions affecting brain health. With over 30 years of scientific validation, its assessments are recognized for their sensitivity in detecting subtle cognitive changes across numerous therapeutic areas.

Recent filings

Filing Released Lang Actions
Posting of Annual Report & Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is an RNS announcement stating that the Company’s Annual Report and Accounts for the year ended 31 December 2025 and the Notice of AGM have been published on the website and dispatched to shareholders. It is a short announcement of publication rather than the reports themselves, so it fits the Report Publication Announcement category.
2026-04-24 English
Results for the year ended 31 December 2025
Earnings Release Classification · 1% confidence The document is an RNS release announcing the full-year financial results for the year ended 31 December 2025. It provides key financial highlights (order book, revenues, EBITDA, cash, borrowing), management commentary (CEO and Chair statements), outlook and operational review. This is a Preliminary Results/Earnings Release rather than the full Annual Report itself (which is noted as available separately on the website). Therefore, it fits the Earnings Release category. FY 2025
2026-04-13 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is an RNS notice titled “Notice of Results” stating that Cambridge Cognition will announce its year-end results on a future date. It does not contain financial results but simply notifies of the upcoming report publication date. This fits the Report Publication Announcement category (RPA).
2026-04-07 English
Appointment of Nominated Adviser and Joint Broker
Regulatory Filings Classification · 1% confidence The document is an RNS disclosure (notice number 3410Z) announcing the appointment of a new Nominated Adviser and Joint Broker (Cavendish Capital Markets) and updates under AIM Rule 17 on director disclosures. It is a regulatory announcement rather than a financial report, management discussion, or capital market transaction like fundraising. This falls under the general Regulatory Filings (RNS) category.
2026-04-07 English
Block Listing Return
Regulatory Filings Classification · 1% confidence The document is a London Stock Exchange RNS release titled “Block Listing Return” filed pursuant to AIM Rule 29 and Schedule Six. It is a routine statutory notification of the balance of unallocated shares under the Company’s share option scheme, with no new issuance, financial performance, or management change detailed. It does not constitute an Annual or Interim Report, Earnings Release, Share Issue announcement, or other specific category. Therefore, it falls into the fallback category for miscellaneous regulatory announcements.
2026-04-01 English
Monument Therapeutics MT1988 First Patient Dosed
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces a specific operational milestone: the dosing of the first patient in a clinical trial by Monument Therapeutics, a company in which Cambridge Cognition holds a 20% stake. As this is a general corporate announcement regarding business operations and does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a Regulatory Filing (RNS).
2026-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.